MX2019010003A - Nuevo uso medico del compuesto iii. - Google Patents

Nuevo uso medico del compuesto iii.

Info

Publication number
MX2019010003A
MX2019010003A MX2019010003A MX2019010003A MX2019010003A MX 2019010003 A MX2019010003 A MX 2019010003A MX 2019010003 A MX2019010003 A MX 2019010003A MX 2019010003 A MX2019010003 A MX 2019010003A MX 2019010003 A MX2019010003 A MX 2019010003A
Authority
MX
Mexico
Prior art keywords
compound iii
medical use
new medical
diseases
polymorphs
Prior art date
Application number
MX2019010003A
Other languages
English (en)
Inventor
Betzemeier Bodo
Werthmann Ulrike
Giovannini Riccardo
Rosenbrock Holger
Ito Masanori
Steven SAND Michael
Adachi Masashi
Brodmann Tobias
kamata Takayuki
KAWABATA Yohei
Jens Marckart Daniel
Nakatani Manabu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019010003A publication Critical patent/MX2019010003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al Compuesto III para uso en el tratamiento de enfermedades en el espectro de la esquizofrenia y otros trastornos psicóticos, primeros episodios de estas enfermedades como el primer episodio psicótico (FEP), recaídas en estas enfermedades, y reducción de recaídas en pacientes con esquizofrenia (REX), a polimorfos del Compuesto III, y composiciones farmacéuticas que comprenden el Compuesto III y/o sus polimorfos.
MX2019010003A 2017-02-23 2018-02-21 Nuevo uso medico del compuesto iii. MX2019010003A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762462621P 2017-02-23 2017-02-23
US201762526393P 2017-06-29 2017-06-29
PCT/EP2018/054221 WO2018153887A1 (en) 2017-02-23 2018-02-21 New medical use of compound iii

Publications (1)

Publication Number Publication Date
MX2019010003A true MX2019010003A (es) 2019-12-16

Family

ID=61569222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010003A MX2019010003A (es) 2017-02-23 2018-02-21 Nuevo uso medico del compuesto iii.

Country Status (11)

Country Link
US (2) US10919898B2 (es)
EP (1) EP3585392A1 (es)
JP (1) JP7053645B2 (es)
KR (1) KR102643197B1 (es)
CN (1) CN110325193B (es)
AU (1) AU2018225373C1 (es)
CA (1) CA3051976A1 (es)
CL (1) CL2019002315A1 (es)
MX (1) MX2019010003A (es)
PH (1) PH12019501926A1 (es)
WO (1) WO2018153887A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008183929A (ja) * 2007-01-26 2008-08-14 Toshiba Corp Ｖｏｒモニタ受信装置及びｖｏｒモニタ受信方法
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
MA33152B1 (fr) * 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
NZ603725A (en) * 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013192225A1 (en) * 2012-06-18 2013-12-27 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US10370336B2 (en) 2015-07-29 2019-08-06 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone PDE9 inhibitors
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors

Also Published As

Publication number Publication date
KR102643197B1 (ko) 2024-03-06
JP2020508320A (ja) 2020-03-19
US20180237445A1 (en) 2018-08-23
AU2018225373C1 (en) 2022-05-12
CN110325193A (zh) 2019-10-11
WO2018153887A1 (en) 2018-08-30
AU2018225373B2 (en) 2022-02-03
JP7053645B2 (ja) 2022-04-12
PH12019501926A1 (en) 2020-07-06
CN110325193B (zh) 2023-05-05
EP3585392A1 (en) 2020-01-01
AU2018225373A1 (en) 2019-08-01
US10919898B2 (en) 2021-02-16
KR20190120298A (ko) 2019-10-23
CA3051976A1 (en) 2018-08-30
US20210130362A1 (en) 2021-05-06
CL2019002315A1 (es) 2019-12-27

Similar Documents

Publication Publication Date Title
GEP20217316B (en) Aromatic sulfonamide derivatives
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
IL285782A (en) Compounds, compositions, and methods for treating disease
MX2023002507A (es) Inhibidores de cd73.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
NZ788133A (en) Cd73 inhibitors
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
SG11202012458RA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
SG11202108636SA (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
EP3841086A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3877383A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
PH12019501926A1 (en) New medical use of compound iii
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EA201991943A1 (ru) Новое медицинское применение соединения iii
EP3846803A4 (en) MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
WO2016187620A3 (en) Anti-cancer compounds
GB202300857D0 (en) New medical uses
GB202212071D0 (en) New medical uses